NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines

Erbaykent-Tepedelen B., Ozmen B., Varisli L., Gonen-Korkmaz C., Debelec-Butuner B., Syed H. M., ...Daha Fazla

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, cilt.414, sa.1, ss.123-128, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 414 Sayı: 1
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.bbrc.2011.09.035
  • Dergi Adı: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.123-128
  • Anahtar Kelimeler: DNA damage response, Topoisomerase inhibitor CPT-11, Prostate cancer, gamma H2AX((S139)) foci, pATM((S1981)), NKX3.1, ANDROGEN RECEPTORS, THERAPY, CDNA, GENE, PHOSPHORYLATION, CARCINOGENESIS, UBIQUITINATION, PROGRESSION, PATHWAYS, FORMS
  • Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

NKX3.1 is an androgen-regulated homeobox gene that encodes a tissue-restricted transcription factor, which plays an important role in the differentiation of the prostate epithelium. Thus, the role of NKX3.1 as a functional topoisomerase I activity enhancer in cell cycle regulation and the DNA damage response (DDR) was explored in prostate cancer cell lines. As an early response to DNA damage following CPT-11 treatment, we found that there was an increase in the gamma H2AX((S139)) foci number and that total phosphorylation levels were reduced in PC-3 cells following ectopic NKX3.1 expression as well as in LNCaP cells following androgen administration. Furthermore, upon drug treatment, the increase in ATM((S1981)) phosphorylation was reduced in the presence of NKX3.1 expression, whereas DNA-PKcs expression was increased. Additionally, phosphorylation of CHK2((T68)) and NBS1((S343)) was abrogated by ectopic NKX3.1 expression, compared with the increasing levels in control PC-3 cells in a time-course experiment. Finally, NKX3.1 expression maintained a high cyclin D1 expression level regardless of drug treatment, while total gamma H2AX((S139)) phosphorylation remained depleted in PC-3, as well as in LNCaP, cells. Thus, we suggest that androgen regulated NKX3.1 maintains an active DDR at the intra S progression and contributes to the chemotherapeutic resistance of prostate cancer cells to DNA damaging compounds. (C) 2011 Elsevier Inc. All rights reserved.